Gupta Rishi
SEC insider (Form 3/4/5 filer). CIK 0001537370. Director at Enliven Therapeutics, Inc. (ELVN) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Feb 12, 2026. Located in BOULDER, CO.
Companies Gupta Rishi has filed insider reports for
- Enliven Therapeutics, Inc. (ELVN): Director
- Turnstone Biologics Corp. (TSBX): Director
Gupta Rishi
CIK: 0001537370
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Feb 12, 2026ELVN
Enliven Therapeutics, Inc.
AwardDirectStock Option (right to buy)
34K shares- - Feb 12, 2026ELVN
Enliven Therapeutics, Inc.
AwardDirectStock Option (right to buy)
1.6K shares- - Aug 8, 2025TSBX
Turnstone Biologics Corp.
Tender OfferIndirect3.1M shares- - Feb 6, 2025ELVN
Enliven Therapeutics, Inc.
AwardDirectStock Option (right to buy)
20.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 12, 2026 |  ELVN Enliven Therapeutics, Inc. | Award Stock Option (right to buy) | 33,989 | - | - | Direct |
| Feb 12, 2026 | ELVN Enliven Therapeutics, Inc. | Award Stock Option (right to buy) | 1,580 | - | - | Direct |
| Aug 8, 2025 |  TSBX Turnstone Biologics Corp. | Tender Offer | 3,099,265 | - | - | Indirect |
| Feb 6, 2025 | ELVN Enliven Therapeutics, Inc. | Award Stock Option (right to buy) | 20,491 | - | - | Direct |
1-4 of 4 transactions